EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

2-arm-PEG-Oligocations Transiently Shield the Liver Sinusoids to Mitigate Off-Target Hepatic Expression of mRNA Lipid Nanoparticles

Anjaneyulu Dirisala, Bhaskar Chatterjee iD, Nguyen Bui Thao Le, Kazuko Toh, Miki Matsui-Masai, Saed Abbasi iD, Xueying Liu, Theofilus A Tockary iD, Nan Qiao, Junichi Ishikawa, Jumpei Norimatsu iD, Yuki Mochida iD und 4 weitere

ACS Nano · 2026

DOI: 10.1021/acsnano.6c08403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Anjaneyulu Dirisala und 15 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-Ku, Kawasaki210-0821, Japan. Hauptthemen laut MEDLINE: Polyethylene Glycols, Nanoparticles, Liver, RNA, Messenger. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology, Japan Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ionizable lipid nanoparticles (iLNPs) are powerful platforms for mRNA-based vaccines and immunotherapies; however, their intrinsic liver tropism compromises both safety and efficacy. Off-target hepatic protein expression from delivered mRNA raises safety concerns, and hepatic clearance limits efficient iLNP delivery to target organs. In this study, we address these challenges in mouse models by stealth-coating the liver sinusoidal endothelial (LSE) wall, the primary gateway for nanoparticle entry into the liver. Specifically, oligocations conjugated with two-armed PEG (2-arm-PEG-oligocations), a clinically relevant material used in oligonucleotide delivery trials, were employed to transiently anchor PEG to the LSE wall with balanced affinity, ensuring robust coating followed by gradual biliary clearance. This approach reduced hepatic protein expression from iLNPs, subsequently administered either systemically or locally, by more than 10-fold. Importantly, the strategy preserved iLNP accumulation in the spleen, a key target organ for vaccines, effectively redirecting iLNPs from the liver to the spleen. Consequently, in vaccine applications, preinjection of the 2-arm-PEG-oligocation preserved or even enhanced vaccination efficacy while minimizing concerns associated with antigen expression in the liver. In applications involving cytokine mRNA therapy, specifically intratumoral interleukin-12 (IL-12) mRNA administration, systemic preinjection of the 2-arm-PEG-oligocation successfully reduced off-target hepatic IL-12 expression and subsequent systemic IL-12 exposure, while maintaining antitumor efficacy. Collectively, these results demonstrate that LSE-wall stealth coating is a generalizable strategy to improve both the safety and efficacy of iLNP-based mRNA vaccines and immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyethylene GlycolsNanoparticlesLiverRNA, MessengerLipidsAnimalsMiceFemaleMice, Inbred C57BLLiposomes

Stichwörter der Autor:innen

hepatic clearanceionizable lipid nanoparticleliver sinusoidmRNA deliverymRNA vaccineoligocationpoly(ethylene glycol)

Substanzen

Polyethylene GlycolsRNA, MessengerLipidsLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-Ku, Kawasaki210-0821, Japan.
  • Department of Advanced Nanomedical Engineering, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo113-8510, Japan.
  • NANO MRNA Co. Ltd. 2-5-1 Atago, Minato-Ku, Tokyo105-6226, Japan.
  • Center for Nanomedicine at the Wilmer Eye Institute, The Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, Maryland21231, United States.
  • Medical Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 1-5 Shimogamohangi-Cho, Sakyo-Ku, Kyoto606-0823, Japan.
  • Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, 4-6-1, Shirokanedai, Minato-Ku, Tokyo108-0071, Japan.

ORCID-Profile: Bhaskar Chatterjee, Saed Abbasi, Theofilus A Tockary, Jumpei Norimatsu, Yuki Mochida, Makoto Oba, Satoshi Uchida

Förderung

  • Japan Agency for Medical Research and Development
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Science and Technology Agency
  • Medical Research Center Initiative for High Depth Omics, Science Tokyo
  • Nanken-Kyoten, Science Tokyo

Zitieren

APA

Dirisala, A., Chatterjee, B., Le, N. B. T., Toh, K., Matsui-Masai, M., Abbasi, S., Liu, X., Tockary, T. A., Qiao, N., Ishikawa, J., Norimatsu, J., Mochida, Y., Fukushima, S., Oba, M., Kataoka, K., & Uchida, S. (2026). 2-arm-PEG-Oligocations Transiently Shield the Liver Sinusoids to Mitigate Off-Target Hepatic Expression of mRNA Lipid Nanoparticles. ACS Nano. https://doi.org/10.1021/acsnano.6c08403

Vancouver

Dirisala A, Chatterjee B, Le NBT, Toh K, Matsui-Masai M, Abbasi S, et al. 2-arm-PEG-Oligocations Transiently Shield the Liver Sinusoids to Mitigate Off-Target Hepatic Expression of mRNA Lipid Nanoparticles. ACS Nano. 2026. doi:10.1021/acsnano.6c08403

BibTeX
@article{Dirisala2026,
  author = {Dirisala, Anjaneyulu and Chatterjee, Bhaskar and Le, Nguyen Bui Thao and Toh, Kazuko and Matsui-Masai, Miki and Abbasi, Saed and Liu, Xueying and Tockary, Theofilus A and Qiao, Nan and Ishikawa, Junichi and Norimatsu, Jumpei and Mochida, Yuki and Fukushima, Shigeto and Oba, Makoto and Kataoka, Kazunori and Uchida, Satoshi},
  title = {2-arm-PEG-Oligocations Transiently Shield the Liver Sinusoids to Mitigate Off-Target Hepatic Expression of mRNA Lipid Nanoparticles},
  journal = {ACS Nano},
  year = {2026},
  doi = {10.1021/acsnano.6c08403}
}
Kostenlos starten →